Shots:
- Following recommendations from the EMA’s CHMP & COMP, the EC has approved Akantior to treat AK among adults & adolescents (≥12yrs.)
- Approval was based on the data from P-III (ODAK) study in AK patients (n=135), published in Ophthalmology, demonstrating that the disease cured in 84.8%, full vision restoration was found in 66.7% with none of them requiring optical cornea transplant and 7.5% needing a therapeutic cornea transplant
- Avanzanite received the exclusive commercialization rights of Akantior in European Economic Area and Switzerland as per an agreement b/w the Avanzanite and SIFI
Ref: SIFI and Avanzanite Bioscience | Image: SIFI and Avanzanite Bioscience| Press Release
Related News:- Regeneron’s Ordspono (Odronextamab) Receives the EC’s Approval to Treat R/R Follicular Lymphoma and Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
